S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Emil D. Kakkis, President and CEO of Ultragenyx Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:RARE), recently executed significant stock transactions, according to a recent SEC filing. On March 3, Kakkis sold 73,434 shares at a weighted average price of $42.10, while on February 28, he sold an additional 25,000 shares at a weighted average price of $42.48. These sales amounted to a total value of approximately $4.15 million. The transactions occurred as the $3.82 billion market cap company trades below its InvestingPro Fair Value, despite challenging profitability metrics.
The transactions were part of Kakkis’s ongoing management of his holdings in Ultragenyx. Following these sales, Kakkis retains a substantial number of shares, both directly and indirectly, through the Emil Kakkis and Jenny Soriano Living Trust. The company maintains strong liquidity with a healthy current ratio of 2.37 and has achieved impressive revenue growth of 29% over the last twelve months. For deeper insights into insider trading patterns and comprehensive financial analysis, InvestingPro subscribers can access detailed research reports covering 1,400+ US stocks.
Additionally, Kakkis acquired shares through awards and stock options, further adjusting his portfolio. These acquisitions were at no cost, resulting in an increase in his overall shareholding in the company. While the stock trades at a relatively high Price/Book multiple, InvestingPro analysis suggests the company remains undervalued based on its Fair Value calculations.
In other recent news, Ultragenyx Pharmaceutical Inc. reported fourth-quarter 2024 earnings that exceeded expectations, driven by strong sales from its Crysvita, Dojolvi, and Evkeeza product lines. Canaccord Genuity responded by raising its price target for Ultragenyx to $136 while maintaining a Buy rating, reflecting confidence in the company’s growth and future product launches. Ultragenyx’s revenue for the fourth quarter was $164.9 million, surpassing estimates from Goldman Sachs and Visible Alpha, which were $159.7 million and $144.2 million, respectively.
Cantor Fitzgerald reiterated its Overweight rating with a $118 price target, noting significant developments in Ultragenyx’s DTX301 program for OTC deficiency and upcoming clinical readouts for setrusumab. H.C. Wainwright maintained a Buy rating with a $95 target, emphasizing the FDA’s acceptance of the BLA for UX111, a gene therapy candidate for MPS IIIA, for Priority Review. Goldman Sachs also maintained a Buy rating with a $78 target, highlighting the company’s robust revenue performance and positive outlook for its pipeline.
Ultragenyx has set a full-year 2025 revenue guidance between $640 million and $670 million, aligning with new estimates from Goldman Sachs and Visible Alpha. The company anticipates several key product launches by 2025, including UX111 for Sanfilippo syndrome and DTX401 for GSD1a. Analysts express optimism about Ultragenyx’s potential for growth, citing its promising pipeline and ongoing clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.